BioWorld

June 15, 2009

View Archived Issues

FDA Review of Gout Drug Sends Savient Stock Soaring

Shares of Savient Pharmaceuticals Inc. skyrocketed 56 percent Friday after FDA drug reviewers said in briefing documents that the firm's gout drug Krystexxa (pegloticase) was effective. (BioWorld Today) Read More

Oscient to Cut Sales Force as it Weighs Possible Sale

Read More

MicroRNA Replacement Via Gene Therapy Stops Liver Cancer Cold

Read More

Allergy Therapeutics Adding £22.4M, Getting New CEO

Read More

CDC Issues First Guidelines Governing Genetic Testing

Read More

CombinatoRx Shares Juiced by Synavive Data Breakdown

Read More

Other News To Note

Read More

Clinic Roundup

Read More

Financings Roundup

Read More